SEC Info  
    Home      Search      My Interests      Help      Sign In      Please Sign In

ResMed Inc. – ‘8-K’ for 8/11/22

On:  Thursday, 8/11/22, at 4:07pm ET   ·   For:  8/11/22   ·   Accession #:  1193125-22-218522   ·   File #:  1-15317

Previous ‘8-K’:  ‘8-K’ on 7/1/22 for 6/28/22   ·   Next & Latest:  ‘8-K/A’ on 8/12/22 for 6/13/22

Magnifying glass tilted right emoji
  in    Show  and   Hints

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 8/11/22  ResMed Inc.                       8-K:2,8,9   8/11/22   11:405K                                   Donnelley … Solutions/FA

Current Report   —   Form 8-K

Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 8-K         Current Report                                      HTML     27K 
 2: EX-99.1     Miscellaneous Exhibit                               HTML    239K 
 6: R1          Document and Entity Information                     HTML     48K 
 9: XML         IDEA XML File -- Filing Summary                      XML     11K 
 7: XML         XBRL Instance -- d392713d8k_htm                      XML     13K 
 8: EXCEL       IDEA Workbook of Financial Reports                  XLSX      8K 
 4: EX-101.LAB  XBRL Labels -- rmd-20220811_lab                      XML     55K 
 5: EX-101.PRE  XBRL Presentations -- rmd-20220811_pre               XML     35K 
 3: EX-101.SCH  XBRL Schema -- rmd-20220811                          XSD     12K 
10: JSON        XBRL Instance as JSON Data -- MetaLinks               12±    18K 
11: ZIP         XBRL Zipped Folder -- 0001193125-22-218522-xbrl      Zip     35K 

‘8-K’   —   Current Report

This is an HTML Document rendered as filed.  [ Alternative Formats ]

 i RESMED INC  i US  i false  i 0000943819 0000943819 2022-08-11 2022-08-11








FORM  i 8-K




Under Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported):

 i August 11, 2022



ResMed Inc.

(Exact Name of Registrant as Specified in Charter)




 i Delaware    i 001-15317    i 98-0152841

(State or Other Jurisdiction

of Incorporation)



File Number)


(I.R.S. Employer

Identification No.)


 i 9001 Spectrum Center Blvd.
 i San Diego,  i California  i 92123

(Address of Principal Executive Offices)

 i (858)  i 836-5000

(Registrant’s telephone number, including area code)



Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:



Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)



Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)



Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))



Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class





Name of each exchange

on which registered

 i Common Stock, $0.004 par value    i RMD    i NYSE

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter)  i 

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act




Item 2.02. Results of Operations and Financial Condition.

On August 11, 2022 we issued the press release furnished as Exhibit 99.1. The press release describes the results of our operations for the quarter and fiscal year ended June 30, 2022.

The information furnished in this Current Report on Form 8-K under Item 2.02 and the attached exhibit shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

Item 8.01. Other Events.

On August 11, 2022 we announced that our board of directors declared a quarterly cash dividend of US $0.44 per share. The dividend will have a record date of August 18, 2022, payable on September 22, 2022. The dividend will be paid in U.S. currency to holders of ResMed’s common stock trading on the New York Stock Exchange. Holders of CHESS Depositary Instruments trading on the Australian Securities Exchange will receive an equivalent amount in Australian currency, based on the exchange rate on the record date, and reflecting the 10:1 ratio between CDIs and NYSE shares. The ex-dividend date will be August 17, 2022, for common stockholders and for CDI holders. ResMed has received a waiver from the ASX’s settlement operating rules, which will allow ResMed to defer processing conversions between its common stock and CDI registers from August 17, 2022, through August 18, 2022, inclusive.

Item 9.01. Financial Statements and Exhibits.

(d)    Exhibits



Description of Document

99.1    Press Release dated August 11, 2022 regarding results of operations
104    Cover Page Interactive Data File (embedded within the Inline XBRL, document)




We have authorized the person whose signature appears below to sign this report on our behalf, in accordance with the Securities Exchange Act of 1934.


Date: August 11, 2022     RESMED INC.

/s/ Brett Sandercock

    Name: Brett Sandercock
    Its: Chief Financial Officer



Dates Referenced Herein   and   Documents Incorporated by Reference

This ‘8-K’ Filing    Date    Other Filings
Filed on / For Period end:8/11/22
 List all Filings 
Filing Submission 0001193125-22-218522   –   Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)

Copyright © 2022 Fran Finnegan & Company LLC – All Rights Reserved.
AboutPrivacyRedactionsHelp — Tue., Sep. 27, 7:52:03.1pm ET